An official website of the United States government
Home
Name
Adria-L-PAM
Alternate names
None
Primary Site
None
Histology
None
Radiation
None
Remarks
None
Drugs for Adria-L-PAM
Name
Alternate Names
Alanine mustard
Alkeran
CB-3025
DL Sarcolysine
DL-O-Sarcolysin
L-Phenylalanine Mustard
L-Sarcolysin
Melfalan
Phenylalanine Mustard
Sarcolysine
Sarkoklorin
Sarkolizin
WR-19813
Abbreviations
L-PAM
MPL
PAM
Category
Chemotherapy
Subcategory
Alkylating agent
NSC Number
8806
008806
57199
Primary Site
Histology
None
Remarks
Alkylating antineoplastic agent. FDA approved uses on multiple myeloma and epithelial non-resectable ovarian carcinoma.
Also used in the high-dose chemotherapy and transplant setting.
Mechanism of action: Analog of nitrogen mustard
Also used in the high-dose chemotherapy and transplant setting.
Mechanism of action: Analog of nitrogen mustard
Coding
This drug should be coded
Name
Alternate Names
14-hydroxy-daunomycin
Adri-blastina (Italy)
Adriamycin
Adriamycin-TM
Caelyx
FT-106
Hydroxydaunomycin
Myocet
Pegylated Liposomal Doxorubicin Hcl
Rubex
S-DOX
Stealth(R) Liposomal Doxorubicin
Abbreviations
ADM
ADR
ADRI
Category
Chemotherapy
Subcategory
Antitumor antibiotic
NSC Number
123127
Primary Site
Histology
None
Remarks
Phase II liver, pancreatic, Phase III MM, prostate Doxorubicin hydrochloride encapsulated in liposomes formulated with methoxypolyethylene glycol (MPEG). FDA approved use on bladder cancer, breast cancer, gastric cancer, leukemia, small cell lung cancer, lymphoma, neuroblastoma, ovarian cancer, sarcoma, thyroid cancer, Wilm's tumor. ALZA Corp, NeoPharm, Pharmacia, Schering-Plough, Sequus. Antitumor antibiotic
Coding
This drug should be coded
